Last reviewed · How we verify
JCARH125
At a glance
| Generic name | JCARH125 |
|---|---|
| Sponsor | Juno Therapeutics, a Subsidiary of Celgene |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (PHASE1, PHASE2)
- Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JCARH125 CI brief — competitive landscape report
- JCARH125 updates RSS · CI watch RSS
- Juno Therapeutics, a Subsidiary of Celgene portfolio CI